New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2013
08:34 EDTPCYCPharmacyclics pullback a buying opportunity, says Credit Suisse
Credit Suisse would use the pullback in Pharmacyclics as a buying opportunity given the multi-billion dollar potential of ibrutinib. Shares are Outperform rated with a $90 price target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
07:35 EDTPCYCPharmacyclics Imbruvica.checks positive, says Deutsche Bank
Subscribe for More Information
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use